FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280565809> ?p ?o ?g. }

• W4280565809 endingPage "72" @default.
• W4280565809 startingPage "64" @default.
• W4280565809 abstract "The availability of new drugs in the chemo-refractory setting opened the way to the concepts of treatment sequencing in mCRC. However, the impact of later line options in the therapeutic route of metastatic colorectal cancer (mCRC) patients and the attrition rate across subsequent lines of therapy are not well established.We performed a pooled analysis of treatments administered after the 2nd disease progression in 1187 mCRC patients enrolled in the randomized phase III TRIBE and TRIBE2 studies, where upfront FOLFOXIRI/bev was compared with FOLFOX or FOLFIRI/bev. Per each line, we assessed the attrition rate, treatment choices and clinical outcomes.625 (53%), 326 (27%) and 136 (11%) patients received a systemic treatment after the 2nd, 3rd and 4th disease progression, respectively. PFS and objective response rate decreased along each line. RAS/BRAF wild-type patients received more likely a 3rd line (75%) compared with RAS (66%, p = 0.005) and BRAF (66%, p = 0.11) mutants. In 3rd line, 67% of RAS/BRAF wild-type patients received anti-EGFRs, achieving longer PFS with respect to other therapies (6.4 vs 3.9 months, p = 0.02). A trend towards longer 3rd line OS was observed in TRIBE patients (9.9 vs 7.2 months, p = 0.05).A relevant attrition rate across subsequent lines of therapy is evident, and more pronounced in RAS and BRAF mutated patients, thus highlighting the relevance of the choice of the upfront treatment. The efficacy of anti-EGFR agents among RAS/BRAF wild-type patients unexposed to anti-EGFRs is higher than other options. The reintroduction of chemotherapy remains frequent in clinical practice.Clinicaltrials. gov Identifiers NCT00719797, NCT02339116." @default.
• W4280565809 created "2022-05-22" @default.
• W4280565809 creator A5001295747 @default.
• W4280565809 creator A5004626743 @default.
• W4280565809 creator A5005516545 @default.
• W4280565809 creator A5026460566 @default.
• W4280565809 creator A5028136107 @default.
• W4280565809 creator A5045260424 @default.
• W4280565809 creator A5051613962 @default.
• W4280565809 creator A5056137510 @default.
• W4280565809 creator A5058514609 @default.
• W4280565809 creator A5058657353 @default.
• W4280565809 creator A5065746326 @default.
• W4280565809 creator A5066696741 @default.
• W4280565809 creator A5072503801 @default.
• W4280565809 creator A5080776095 @default.
• W4280565809 creator A5081985776 @default.
• W4280565809 creator A5083540572 @default.
• W4280565809 creator A5083651413 @default.
• W4280565809 creator A5087670194 @default.
• W4280565809 date "2022-07-01" @default.
• W4280565809 modified "2023-09-30" @default.
• W4280565809 title "Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies" @default.
• W4280565809 cites W1018331845 @default.
• W4280565809 cites W1993780950 @default.
• W4280565809 cites W2106090525 @default.
• W4280565809 cites W2111851685 @default.
• W4280565809 cites W2115735904 @default.
• W4280565809 cites W2124033094 @default.
• W4280565809 cites W2147834058 @default.
• W4280565809 cites W2148727529 @default.
• W4280565809 cites W2153636004 @default.
• W4280565809 cites W2159303174 @default.
• W4280565809 cites W2160373161 @default.
• W4280565809 cites W2168579528 @default.
• W4280565809 cites W2336815607 @default.
• W4280565809 cites W2470575266 @default.
• W4280565809 cites W2604405550 @default.
• W4280565809 cites W2774682757 @default.
• W4280565809 cites W2783112448 @default.
• W4280565809 cites W2790254562 @default.
• W4280565809 cites W2792663627 @default.
• W4280565809 cites W2805752794 @default.
• W4280565809 cites W2898902386 @default.
• W4280565809 cites W2947553355 @default.
• W4280565809 cites W2955480906 @default.
• W4280565809 cites W2977895282 @default.
• W4280565809 cites W2998019136 @default.
• W4280565809 cites W3009139795 @default.
• W4280565809 cites W3031660105 @default.
• W4280565809 cites W3052790525 @default.
• W4280565809 cites W3087229737 @default.
• W4280565809 cites W3092089341 @default.
• W4280565809 cites W3110528877 @default.
• W4280565809 cites W3118299315 @default.
• W4280565809 cites W3134887329 @default.
• W4280565809 cites W3155701827 @default.
• W4280565809 cites W3158668760 @default.
• W4280565809 cites W3201933598 @default.
• W4280565809 cites W4200222683 @default.
• W4280565809 doi "https://doi.org/10.1016/j.ejca.2022.04.019" @default.
• W4280565809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35594613" @default.
• W4280565809 hasPublicationYear "2022" @default.
• W4280565809 type Work @default.
• W4280565809 citedByCount "2" @default.
• W4280565809 countsByYear W42805658092022 @default.
• W4280565809 countsByYear W42805658092023 @default.
• W4280565809 crossrefType "journal-article" @default.
• W4280565809 hasAuthorship W4280565809A5001295747 @default.
• W4280565809 hasAuthorship W4280565809A5004626743 @default.
• W4280565809 hasAuthorship W4280565809A5005516545 @default.
• W4280565809 hasAuthorship W4280565809A5026460566 @default.
• W4280565809 hasAuthorship W4280565809A5028136107 @default.
• W4280565809 hasAuthorship W4280565809A5045260424 @default.
• W4280565809 hasAuthorship W4280565809A5051613962 @default.
• W4280565809 hasAuthorship W4280565809A5056137510 @default.
• W4280565809 hasAuthorship W4280565809A5058514609 @default.
• W4280565809 hasAuthorship W4280565809A5058657353 @default.
• W4280565809 hasAuthorship W4280565809A5065746326 @default.
• W4280565809 hasAuthorship W4280565809A5066696741 @default.
• W4280565809 hasAuthorship W4280565809A5072503801 @default.
• W4280565809 hasAuthorship W4280565809A5080776095 @default.
• W4280565809 hasAuthorship W4280565809A5081985776 @default.
• W4280565809 hasAuthorship W4280565809A5083540572 @default.
• W4280565809 hasAuthorship W4280565809A5083651413 @default.
• W4280565809 hasAuthorship W4280565809A5087670194 @default.
• W4280565809 hasConcept C121608353 @default.
• W4280565809 hasConcept C126322002 @default.
• W4280565809 hasConcept C143998085 @default.
• W4280565809 hasConcept C2776705615 @default.
• W4280565809 hasConcept C2778260052 @default.
• W4280565809 hasConcept C2780962732 @default.
• W4280565809 hasConcept C2781187634 @default.
• W4280565809 hasConcept C526805850 @default.
• W4280565809 hasConcept C71924100 @default.
• W4280565809 hasConceptScore W4280565809C121608353 @default.
• W4280565809 hasConceptScore W4280565809C126322002 @default.
• W4280565809 hasConceptScore W4280565809C143998085 @default.

• next